Nurix Therapeutics Presents Positive Results From the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

GlobeNewswireOct 19 08:00 ET

Express News | Nurix Therapeutics Expands Its Board of Directors With the Addition of Drug Commercialization Expert Anil Kapur

ReutersOct 16 16:35 ET

Press Release: Nurix Therapeutics Expands Its Board of Directors With the Addition of Drug Commercialization Expert Anil Kapur

Dow JonesOct 16 16:35 ET

Oppenheimer Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $35

Moomoo NewsOct 15 16:32 ET · Ratings

Nurix Therapeutics Price Target Raised to $35 From $30 at Oppenheimer

TipRanksOct 15 15:30 ET

J.P. Morgan Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Cuts Target Price to $31

Moomoo NewsOct 15 09:33 ET · Ratings